Collplant Biotechnologies Ltd (CLGN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $14.27M
Last updated: Nov 13, 2026 at 4:00 PM ET
Collplant Biotechnologies Ltd (CLGN) Earnings: Report Dates and Results
Collplant Biotechnologies (CLGN) is expected to report earnings on Nov 24, 2026. In the quarter ended Jun 30, 2026, Collplant Biotechnologies reported EPS of -$1.89, above the -$2.40 estimate. It beat the EPS estimate in 1 of the last 8 quarters.
Earnings
Performance (10Y)
Next Report
CLGN has an expected report date of Nov 24, 2026.
CLGN Earnings Call
The latest CLGN earnings call transcript on file is labeled 2024Q3.
Read the 2024Q3 transcriptEarnings History
Of the 28 quarters below that had an estimate, CLGN beat 6, missed 21 and matched 1. Revenue for the quarter ended Jun 30, 2026 was $108000, down 39.7% from $179000 a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | -$1.89 | -$2.40 | -$2.40 - -$2.40 | +21.25% | Beat | N/A | 1 | 0 up, 0 down | Sep 30, 2026 | $108000 |
| Mar 31, 2026 | -$0.23 | -$0.13 | N/A | -72.51% | Miss | N/A | 1 | 0 up, 0 down | May 29, 2026 | $73000 |
| Dec 31, 2025 | -$0.25 | -$0.19 | -$0.19 - -$0.19 | -31.58% | Miss | N/A | 1 | 0 up, 1 down | Mar 26, 2026 | $60000 |
| Sep 30, 2025 | -$0.27 | $0.16 | -$0.07 - $0.38 | -268.75% | Miss | N/A | 2 | 0 up, 1 down | Nov 26, 2025 | $77000 |
| Jun 30, 2025 | -$0.28 | -$0.10 | -$0.10 - -$0.10 | -180.00% | Miss | N/A | 1 | 0 up, 1 down | Aug 20, 2025 | $179000 |
| Mar 31, 2025 | -$0.13 | -$0.04 | N/A | -225.00% | Miss | N/A | N/A | 0 up, 0 down | May 28, 2025 | $2.06M |
| Dec 31, 2024 | -$0.33 | -$0.28 | N/A | -20.00% | Miss | N/A | N/A | 0 up, 0 down | Mar 26, 2025 | $164000 |
| Sep 30, 2024 | -$0.38 | -$0.28 | N/A | -35.71% | Miss | N/A | N/A | 0 up, 0 down | Nov 27, 2024 | $4000 |
| Jun 30, 2024 | -$0.37 | -$0.27 | -$0.35 - -$0.19 | -37.04% | Miss | -175.5% | 2 | 0 up, 0 down | Aug 20, 2024 | $249000 |
| Mar 31, 2024 | -$0.37 | -$0.35 | -$0.35 - -$0.35 | -5.71% | Miss | N/A | 1 | 0 up, 0 down | Apr 4, 2024 | $98000 |
| Dec 31, 2023 | -$0.24 | -$0.07 | -$0.38 - $0.24 | -242.86% | Miss | N/A | 2 | 0 up, 0 down | Jan 25, 2024 | $299000 |
| Sep 30, 2023 | -$0.38 | $0.03 | -$0.45 - $0.41 | N/A | N/A | N/A | 3 | 0 up, 0 down | Nov 29, 2023 | $43000 |
| Jun 30, 2023 | $0.49 | $0.08 | -$0.41 - $0.44 | +512.50% | Beat | N/A | 2 | 0 up, 0 down | Aug 24, 2023 | $10.18M |
| Mar 31, 2023 | -$0.33 | -$0.39 | -$0.39 - -$0.11 | +15.38% | Beat | N/A | 3 | 0 up, 0 down | May 24, 2023 | $433000 |
| Dec 31, 2022 | -$0.38 | -$0.31 | -$0.42 - -$0.21 | -22.58% | Miss | N/A | 2 | 0 up, 0 down | Mar 29, 2023 | $58000 |
| Sep 30, 2022 | -$0.40 | $0.48 | N/A | -183.33% | Miss | N/A | 1 | 0 up, 0 down | Dec 1, 2022 | $109000 |
| Jun 30, 2022 | -$0.39 | -$0.08 | -$0.08 - -$0.08 | -387.50% | Miss | N/A | 1 | 0 up, 0 down | Aug 25, 2022 | $66000 |
| Mar 31, 2022 | -$0.36 | -$0.14 | -$0.14 - -$0.14 | -157.14% | Miss | -140.9% | 1 | 0 up, 0 down | May 26, 2022 | $66000 |
| Dec 31, 2021 | -$0.30 | -$0.29 | -$0.29 - -$0.29 | -3.45% | Miss | N/A | 1 | 0 up, 0 down | Mar 24, 2022 | $310000 |
| Sep 30, 2021 | -$0.29 | -$0.27 | -$0.29 - -$0.27 | -7.41% | Miss | -363.6% | 2 | N/A | Nov 18, 2021 | $140000 |
| Jun 30, 2021 | -$0.30 | -$0.27 | -$0.27 - $0.07 | -11.11% | Miss | N/A | 2 | N/A | Aug 19, 2021 | $691000 |
| Mar 31, 2021 | $0.88 | $0.80 | $0.21 - $0.80 | +10.00% | Beat | N/A | 2 | N/A | May 27, 2021 | $14.50M |
| Dec 31, 2020 | -$0.42 | -$0.30 | -$0.32 - -$0.28 | -40.00% | Miss | N/A | 2 | N/A | Mar 26, 2021 | $557000 |
| Sep 30, 2020 | $0.11 | $1.96 | -$0.60 - $19.00 | -94.39% | Miss | N/A | 2 | N/A | Dec 1, 2020 | $4.15M |
| Jun 30, 2020 | -$0.20 | -$0.25 | -$0.25 - -$0.06 | +20.00% | Beat | N/A | 2 | N/A | Aug 28, 2020 | $823000 |
| Mar 31, 2020 | -$0.21 | -$0.45 | -$0.45 - -$0.01 | +53.33% | Beat | N/A | 2 | N/A | Apr 1, 2020 | $609000 |
| Dec 31, 2019 | -$0.86 | -$0.70 | N/A | -22.86% | Miss | N/A | 2 | N/A | Mar 18, 2020 | $439000 |
| Sep 30, 2019 | -$0.41 | -$0.26 | N/A | -57.69% | Miss | N/A | N/A | N/A | Nov 29, 2019 | $679000 |
| Jun 30, 2019 | -$0.17 | N/A | N/A | N/A | N/A | N/A | N/A | 0 up, 0 down | Sep 26, 2019 | $606000 |
| Mar 31, 2019 | -$0.01 | -$0.01 | N/A | 0.00% | In line | N/A | N/A | 0 up, 0 down | Apr 1, 2019 | $594000 |
| Dec 31, 2018 | -$0.29 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 31, 2019 | N/A |
| Sep 30, 2018 | -$0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 29, 2018 | $225046 |
| Jun 30, 2018 | -$0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Sep 21, 2018 | $178504 |
| Mar 31, 2018 | -$0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 24, 2018 | $221835 |
| Dec 31, 2017 | -$0.51 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 21, 2018 | $273909 |
| Sep 30, 2017 | -$0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 20, 2017 | $74510 |
| Jun 30, 2017 | -$0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Sep 1, 2017 | $57630 |
| Mar 31, 2017 | -$0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 29, 2017 | $69549 |
| Dec 31, 2016 | -$0.02 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 27, 2017 | $51407 |
| Sep 30, 2016 | -$0.05 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 24, 2016 | $24504 |
Estimates made before a stock split are shown on the same share basis as the reported EPS.
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.93, after -$1.45 the year before. It was -$0.11 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.93 | N/A |
| Dec 31, 2024 | -$1.45 | N/A |
| Dec 31, 2023 | -$0.46 | N/A |
| Dec 31, 2022 | -$1.53 | N/A |
| Dec 31, 2021 | -$0.01 | N/A |
| Dec 31, 2020 | -$0.72 | N/A |
| Dec 31, 2019 | -$1.45 | N/A |
| Dec 31, 2018 | -$0.32 | N/A |
| Dec 31, 2017 | -$0.54 | N/A |
| Dec 31, 2016 | -$0.11 | N/A |
Earnings Calls
The 2 most recent earnings calls are listed below; the latest, 2024Q3 for the period ended Sep 30, 2024, runs about 3,000 words across 4 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2024Q3 | Sep 30, 2024 | 2,959 | 4 | |
| 2024Q2 | Jun 30, 2024 | 3,518 | 6 |
2024Q3 Earnings Call
Opening remarks
Dory Kurowski Moderator I would like to welcome everyone to CollPlant Biotechnologies Financial Results Conference Call to discuss the results for the third quarter ended September 30, 2024, where management will also provide a corporate business update. With us on the call today from CollPlant are Yehiel Tal, Chief Executive Officer, who will provide an overview of the company's programs and associated updates; and Eran Rotem, Deputy CEO and Chief Financial Officer, who will provide a summary of CollPlant financial results for the second quarter ending September 30, 2024. Both will be able to answer questions at the end of the call. Before we get started, I’d like to remind everyone that statements made on this conference call may include forward-looking statements. Actual events or results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties and other factors including those set forth in the Risk Factors section of CollPlant's filings with the Securities and Exchange Commission. These filings can be found at www.sec.gov or on CollPlant's website at www.collplant.com. In addition, any forward-looking statements made on this call represent CollPlant's views only as of today, November 27, 2024, and should not be relied upon as representing the company's views as of any subsequent date. CollPlant's management specifically disclaims any obligation to update or revise any of these forward-looking statements. Finally, CollPlant management will refer to certain financial measures not reported in accordance with GAAP on this call. You can find reconciliations of these non-GAAP financial measures to the GAAP financial measures in the earnings press release that CollPlant published earlier today and which is available on CollPlant's website at ir.collplant.com. Now let me turn the call over to Yehiel Tal, Chief Executive Officer of CollPlant Biotechnologies. Please go ahead, sir.
Yehiel Tal CEO Good morning, everyone, and thank you for joining us today on CollPlant's investor conference call to discuss our third quarter 2024 financial results and corporate development, as we pursue our mission to be a leader in the field of regenerative medicine. I will start with an update on the regenerative breast implant program. This quarter, we continued to advance our preclinical study that includes 200cc commercial-sized breast implants composed of our proprietary rhCollagen-based bioinks and printed with the Stratasys 3D printer. This study is critical to advancing our technology towards a marketed product and creating significant shareholder value. This most recent preclinical study launched in Q3 using clinical size implants has been designed to assess product performance and safety and is implementing a new and more suitable animal model, refined surgical protocol, and optimized implant design and formulation.
Frequently Asked Questions About CLGN
When is Collplant Biotechnologies's next earnings date?
Collplant Biotechnologies's next earnings report is expected for Nov 24, 2026.
Did CLGN beat earnings estimates last quarter?
Yes. Collplant Biotechnologies reported EPS of -$1.89 for the quarter ended Jun 30, 2026, above the -$2.40 estimate, a 21.25% surprise.
How often does CLGN beat earnings estimates?
Collplant Biotechnologies beat the EPS estimate in 1 of the last 8 quarters, with an average surprise of -101.54%.
CLGN pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors